| Not Yet Recruiting | Access to Hepatitis C Treatment in Cameroon: Comparison of a Simplified Test and Treat Strategy to a Standard NCT07098481 | ANRS, Emerging Infectious Diseases | Phase 4 |
| Recruiting | Hepatitis C Tracker Study NCT06870019 | University of Southern California | N/A |
| Recruiting | C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV NCT07037277 | Atea Pharmaceuticals, Inc. | Phase 3 |
| Not Yet Recruiting | Screening, Treatment, and Eradication of Hep C NCT05071261 | Liver Institute PLLC | — |
| Recruiting | Screening for Hepatitis c in People Who Inject Drugs in Armenia-Colombia NCT06463912 | Asociación Colombiana de Hepatología | — |
| Recruiting | Characterization of Immune Genotypes and Antibody Profiles to Foster the discoVERY of diagnosticbioMARKERS of NCT06718530 | Centro di Riferimento Oncologico - Aviano | — |
| Recruiting | Adult Screening for Hepatitis c and Linkage to Treatment in Hospitals in Colombia NCT06155006 | Asociación Colombiana de Hepatología | — |
| Recruiting | Early Detection of HCV in Injection Drug Users NCT06431945 | Institute of Health Information and Statistics of the Czech Republic | — |
| Completed | Relinking Diagnosed But Untreated HCV Patients Back Into Care. NCT05975216 | Universitair Ziekenhuis Brussel | — |
| Unknown | Simplification and Test and Treat Strategies Towards Hepatitis C Eliminationplatform" in China(STAT) NCT05906459 | Huashan Hospital | — |
| Completed | Digital Community to Improve Health in Rural Areas NCT05363865 | University of Pennsylvania | N/A |
| Unknown | Implementing HCV Treatment for High-risk Populations in Austin, Texas NCT05460130 | University of Texas at Austin | N/A |
| Unknown | Pharmacist-led Hepatitis C Management NCT04322981 | University Health Network, Toronto | Phase 4 |
| Completed | CARES-HCV: Promoting Screening Uptake Among Diverse Baby Boomers NCT04980157 | H. Lee Moffitt Cancer Center and Research Institute | — |
| Unknown | Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) for Patients With Hepatitis C Virus Infection NCT05092074 | National Taiwan University Hospital | — |
| Withdrawn | Study of AT-777 in Healthy Subjects and AT-777 in Combination With AT-527 in HCV-Infected Subjects NCT04309734 | Atea Pharmaceuticals, Inc. | Phase 1 / Phase 2 |
| Active Not Recruiting | Interventions to Curb Hepatitis C Reinfections Among Men Who Have Sex With Men NCT04156945 | Public Health Service of Amsterdam | N/A |
| Completed | Evaluation of the Safety and Effectiveness of Direct-acting Antiviral Drugs in the Treatment of Hepatitis C in NCT05452187 | Hospital Mutua de Terrassa | — |
| Unknown | HCV Reinfection in in HIV/HCV-coinfected Patients Achieving SVR by Antiviral Therapy NCT04768517 | National Taiwan University Hospital | — |
| Unknown | HCV Reinfection in HD Patients Achieving SVR NCT04732832 | National Taiwan University Hospital | — |
| Unknown | Pharmacokinetics of Sofosbuvir/Daclatasvir in HCV-infected Lactating Women NCT04852614 | Ain Shams University | — |
| Completed | DBS Evaluation of Fujirebio INNOTEST® HCV Ab IV NCT04317729 | Foundation for Innovative New Diagnostics, Switzerland | N/A |
| Completed | Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir (SOF/VEL) Fixed-Dose Combination (FDC) NCT04211909 | Gilead Sciences | Phase 3 |
| Completed | Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination for 12 Weeks in NCT04112303 | Gilead Sciences | Phase 3 |
| Unknown | Prevalence of HCV in HIV-negative MSM NCT04005248 | Erasmus Medical Center | N/A |
| Completed | Evaluation Study of HCV RDTs in Fresh Samples NCT04139941 | Foundation for Innovative New Diagnostics, Switzerland | — |
| Unknown | Telemedicine for Linkage to Care People Who Injected Drugs With Hepatitis C NCT04035980 | University of La Laguna | N/A |
| Completed | Study of AT-527 in Combination With Daclatasvir in Subjects With Hepatitis C Virus (HCV) Infection NCT04019717 | Atea Pharmaceuticals, Inc. | Phase 2 |
| Unknown | Study of Seraprevir in Combination With Sofosbuvir in Chronic Genotype 2,3,6 Hepatitis C Virus Infection Patie NCT04111367 | Ginkgopharma CO., LTD | Phase 2 |
| Completed | Integrating Hepatitis C Screening With Dried Blood Spot Testing Into Colorectal Cancer Screening NCT04037046 | University of La Laguna | N/A |
| Terminated | Study to Investigate Pharmacokinetics, Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX NCT03820258 | Gilead Sciences | Phase 2 |
| Unknown | Study of Seraprevir in Combination With Sofosbuvir in Chronic Genotype 1 Hepatitis C Virus Infection Patients NCT04001608 | Ginkgopharma CO., LTD | Phase 3 |
| Unknown | Liver Elastography in Patients Undergoing Treatment for Hepatitis C NCT03434470 | Haukeland University Hospital | — |
| Completed | Ledipasvir/Sofosbuvir in Adults With Chronic Hepatitis C Virus (HCV) Infection Who Are on Dialysis for End Sta NCT03036839 | Gilead Sciences | Phase 2 |
| Completed | Safety And Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination for 12 Weeks in Adults Who P NCT03118843 | Gilead Sciences | Phase 3 |
| Completed | Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) Infe NCT03074331 | Gilead Sciences | Phase 3 |
| Completed | Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir in Adolescents and Children With Chroni NCT03022981 | Gilead Sciences | Phase 2 |
| Completed | Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 Weeks i NCT02994056 | Gilead Sciences | Phase 2 |
| Completed | Ombitasvir /Paritaprevir/Ritonavir Plus Ribavirin on HCV GT4 NCT04378608 | Beni-Suef University | Phase 1 / Phase 2 |
| Completed | Efficacy and Safety of Sofosbuvir/Velpatasvir ± Ribavirin for 12 Weeks in Adults With Chronic HCV Infection an NCT02996682 | Gilead Sciences | Phase 3 |
| Completed | Efficacy and Safety of Glecaprevir (ABT-493)/Pibrentasvir (ABT 530) (GLE/PIB) in Combination With Sofosbuvir a NCT02939989 | AbbVie | Phase 3 |
| Completed | Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed Dose Combination in the Treatment of Hepatitis C Virus (HCV NCT02868242 | Gilead Sciences | Phase 2 |
| Completed | Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination (FDC) and Sofosbuvir/Velpatasvir FDC and NCT02781558 | Gilead Sciences | Phase 2 |
| Completed | Sofosbuvir/Velpatasvir Fixed Dose Combination in Participants With Chronic Hepatitis C Virus Infection Who Hav NCT02781571 | Gilead Sciences | Phase 2 |
| Completed | Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 or 24 Weeks in Participants With Chronic Ge NCT02822794 | Gilead Sciences | Phase 3 |
| Completed | Sofosbuvir/Velpatasvir Fixed-Dose Combination in HCV-Infected Adults Who Are Undergoing Liver Transplantation NCT02728206 | Gilead Sciences | Phase 2 |
| Completed | A Study to Evaluate the Efficacy and Safety of Experimental Drugs ABT- 493/ABT-530 in Adults With Chronic Hepa NCT02738138 | AbbVie | Phase 3 |
| Completed | Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Participants With Chronic NCT02671500 | Gilead Sciences | Phase 3 |
| Completed | Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Participants With Chronic Genotype 2 HCV Infectio NCT02738333 | Gilead Sciences | Phase 3 |
| Completed | Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination in Participants With Chronic Hepatitis C NCT02722837 | Gilead Sciences | Phase 3 |
| Completed | Safety and Efficacy of SOF/VEL/VOX FDC for 8 Weeks and SOF/VEL for 12 Weeks in Adults Chronic Genotype 3 HCV I NCT02639338 | Gilead Sciences | Phase 3 |
| Completed | Safety and Efficacy of SOF/VEL/VOX FDC for 12 Weeks and SOF/VEL for 12 Weeks in DAA-Experienced Adults With Ch NCT02639247 | Gilead Sciences | Phase 3 |
| Completed | Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination in Adults With Chronic HCV and HBV Coinfec NCT02613871 | Gilead Sciences | Phase 3 |
| Completed | A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genoty NCT02642432 | AbbVie | Phase 3 |
| Terminated | Efficacy and Safety of Ledipasvir/Sofosbuvir, With or Without Ribavirin, in HCV Infected Participants Who Have NCT02600351 | Gilead Sciences | Phase 3 |
| Terminated | A Registry for Adolescent and Pediatric Participants Who Received a Gilead Hepatitis C Virus Direct Acting Ant NCT02510300 | Gilead Sciences | — |
| Completed | Use-Results Surveillance Study of Sovaldi® Plus Copegus® in Japanese Patients With Chronic Genotype 2 Hepatiti NCT02537379 | Gilead Sciences | — |
| Completed | Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination, With or Without Ribavirin, in Egyptian Ad NCT02487030 | Gilead Sciences | Phase 3 |
| Completed | Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination With or Without Ribavirin in NCT02536313 | Gilead Sciences | Phase 2 |
| Completed | Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepat NCT02480712 | Gilead Sciences | Phase 3 |
| Completed | A Multiple-Dose Study to Evaluate MK-1075 in Hepatitis C Virus (HCV) Infected Participants (MK-1075-004) NCT02461563 | Merck Sharp & Dohme LLC | Phase 1 |
| Completed | Safety and Efficacy of Ledipasvir/Sofosbuvir in Adults With Chronic HCV Infection NCT02472886 | Gilead Sciences | Phase 3 |
| Completed | Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination Administered in Patients Infected With Chr NCT02350569 | Gilead Sciences | Phase 2 |
| Completed | Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination Tablet With Ribavirin for 12 Wee NCT02413593 | Gilead Sciences | Phase 2 |
| Completed | Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 or 24 Weeks in Genotype 1 or 4 HCV Infected Adults With Si NCT02301936 | Gilead Sciences | Phase 2 |
| Completed | Sofosbuvir/Pegylated-interferon Plus Ribavirin With HCV Genotype 4 NCT04382339 | Beni-Suef University | Phase 1 / Phase 2 |
| Completed | Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection NCT02346721 | Gilead Sciences | Phase 3 |
| Completed | Safety and Efficacy of Voxilaprevir Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic NCT02378935 | Gilead Sciences | Phase 2 |
| Completed | Safety and Efficacy of Voxilaprevir Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic NCT02378961 | Gilead Sciences | Phase 2 |
| Terminated | A Registry for Participants With Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment With NCT02292706 | Gilead Sciences | — |
| Completed | Efficacy And Safety Of Sofosbuvir/Velpatasvir Fixed Dose Combination With Ribavirin in Chronic HCV Infected Ad NCT02300103 | Gilead Sciences | Phase 2 |
| Completed | Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination +/- Ribavirin in Adolescents and Children NCT02249182 | Gilead Sciences | Phase 2 |
| Completed | Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination (FDC) for 12 or 24 Weeks in Kidn NCT02251717 | Gilead Sciences | Phase 2 |
| Completed | Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 12 NCT02220998 | Gilead Sciences | Phase 3 |
| Completed | Ledipasvir/Sofosbuvir Fixed-Dose Combination on Cerebral Metabolism and Neurocognition in Treatment-Naive and NCT02219685 | Gilead Sciences | Phase 2 |
| Completed | Safety and Efficacy of Sofosbuvir + Ribavirin in Adolescents and Children With Genotype 2 or 3 Chronic HCV Inf NCT02175758 | Gilead Sciences | Phase 2 |
| Completed | Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic HCV Infection NCT02201940 | Gilead Sciences | Phase 3 |
| Completed | Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 24 NCT02201953 | Gilead Sciences | Phase 3 |
| Completed | Ledipasvir/Sofosbuvir Fixed-Dose Combination and Vedroprevir With or Without Ribavirin in Treatment-Experience NCT02226549 | Gilead Sciences | Phase 2 |
| Completed | Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection and Child-Pugh Class B Cirr NCT02201901 | Gilead Sciences | Phase 3 |
| Completed | Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Voxilaprevir in Adults Wit NCT02185794 | Gilead Sciences | Phase 1 |
| Completed | Efficacy and Safety of Sofosbuvir+Ribavirin in Genotype 2 HCV-infected U.S. Veterans With Cirrhosis NCT02128542 | Gilead Sciences | Phase 4 |
| Completed | Absolute Bioavailability of BMS-791325 NCT02112110 | Bristol-Myers Squibb | Phase 1 |
| Completed | Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Chronic Hepatitis NCT02114177 | Janssen Infectious Diseases BVBA | Phase 3 |
| Completed | UNITY 3: A Japanese Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 in Subjects With Genotype 1 Chronic NCT02123654 | Bristol-Myers Squibb | Phase 3 |
| Completed | Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Genotype 1 Chronic NCT02114151 | Janssen Infectious Diseases BVBA | Phase 3 |
| Completed | A Multipart, Open-label Study to Evaluate the Safety and Efficacy of ABT-450/r/ABT-267 With and Without ABT-33 NCT01939197 | AbbVie | Phase 2 / Phase 3 |
| Completed | A Phase 3, Comparative Study of Asunaprevir and Daclatasvir Combination Therapy Versus Telaprevir Therapy in J NCT01718145 | Bristol-Myers Squibb | Phase 3 |
| Completed | A Study in Healthy Participants Investigating the Safety, Tolerability and Plasma Pharmacokinetics (PK) of Sin NCT01482611 | Janssen R&D Ireland | Phase 1 |
| Completed | Study of pegInterferon Alfa-2a, Ribavirin, and Daclatasvir (BMS-790052) With or Without BMS-650032 for Partici NCT01428063 | Bristol-Myers Squibb | Phase 2 |
| Unknown | Herpes Simplex Type 2 Co-infection in Veterans With Chronic Hepatitis C NCT01037621 | G.V. (Sonny) Montgomery VA Medical Center | Phase 1 |
| Terminated | Safety and Efficacy Study in Hepatitis C Patients With PHN121 NCT01052090 | PhytoHealth Corporation | Phase 1 / Phase 2 |
| Completed | A Follow-up Study to Assess Resistance to ABT-072 in HCV-infected Subjects Administered ABT-072 in Prior ABT-0 NCT00872196 | AbbVie (prior sponsor, Abbott) | Phase 2 |
| Completed | Effect of Immunosuppression Drug Weaning on Hepatitis C Virus (HCV)-Induced Liver Damage After Liver Transplan NCT00668369 | Hospital Clinic of Barcelona | Phase 2 |
| Completed | Evaluation of a Multi-disciplinary Approach for the Treatment of Hepatitis C in IDUs (HI-LO Study) NCT00399672 | University of British Columbia | N/A |
| Unknown | Genetic Polymorphisms of Interleukin-10 and TNF-α on Outcome of HCV-Related Chronic Liver Disease NCT00630006 | Kaohsiung Medical University Chung-Ho Memorial Hospital | N/A |
| Completed | Antiviral Activity and Safety of 3 Different Doses of Mifepristone in Hepatitis C Infected Patients NCT00255177 | VGX Pharmaceuticals, LLC | Phase 2 |
| Completed | Pender Assisted Therapy (PATh) - Prospective Study of the Treatment of HCV NCT00247884 | University of British Columbia | — |
| Completed | 14 vs 24 Weeks HCV Treatment to Genotype 2/3 Patients With Rapid Virological Response NCT00308048 | Ullevaal University Hospital | Phase 3 |
| Completed | Treatment With IFN After Curative Resection of HCC in HCV-Related Cirrhosis NCT00273247 | National Cancer Institute, Milan | Phase 3 |
| Approved For Marketing | Expanded Access to Glecaprevir/ Pibrentasvir NCT03123965 | AbbVie | — |